Hagop Kantarjian, MD, on Treating Philadelphia Chromosome–Positive ALL

2014 ASH Annual Meeting

Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 797, “First Results of the Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Patients,” presented by Sabina Chiaretti, MD, PhD, and abstract 798, “Nilotinib and Chemotherapy for First-Line Treatment in Elderly Patients with De Novo Philadelphia Chromosome/BCR-ABL1–Positive Acute Lymphoblastic Leukemia (ALL): A Trial of the European Working Group for Adult ALL (EWALL-PH-02),” presented by Oliver G. Ottman, MD.

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Clinical Trial Results for AML, MDS, and CMML Treatment

James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Richard M. Stone, MD of the Dana-Farber Cancer Institute, discuss three clinical trials: different doses of daunorubicin for AML; comparing azacitidine plus lenolidomide to vorinostat vs azacitidine monotherapy in MDS and CMML; and sorafenib vs placebo in addition to standard treatment for AML.

Lymphoma

Julie M. Vose, MD

Julie M. Vose, MD, MBA, FASCO, on the AETHERA trial

Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 673, “The AETHERA Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma,” presented by Craig H. Moskowitz, MD.

May

Today In Oncology

Hagop Kantarjian, MD, on Treating Philadelphia Chromosome–Positive ALL

Related Videos

Alan F. List, MD, on Sotatercept in Lower-Risk Myelodysplastic Syndromes

Ayalew Tefferi, MD, on New Models of Prognostication for Myelofibrosis

Richard M. Stone, MD, on the SAL-SORAML Trial

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Clinical Trial Results for AML, MDS, and CMML Treatment

Julie M. Vose, MD, MBA, FASCO, on the AETHERA trial

Plasma miR-371a-3p Predicts Recurrence in Stage I Testicular Cancer: Interim Results From the CLIMATE Study

Promising Signal Only ctDNA in Early Breast Cancer Not Yet Ready for Clinical Use

AI Pathology Framework for Biological Understanding of Tumors

AI Model Enables Earlier Detection of Pancreatic Cancer on Routine CT Scans

Breast Density Reduction: Endoxifen vs Tamoxifen